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The etiology and pathogenesis of Parkinson’s disease (PD) are tightly linked to the gain-of-function of a-
synuclein. However, gradual accumulation of a-synuclein aggregates in dopaminergic neurons of sub-
stantia nigra pars compacta (SNpc) leads to the depletion of the functional pool of soluble a-synuclein, and
therefore, creates loss-of-function conditions, particularly in presynaptic terminals of these neurons.
Studies of how this late-onset depletion of a protein involved in many important steps of neurotrans-
mission contributes to PD progression and particularly, to worsening the nigrostriatal pathology at late
stages of the disease are limited and obtained data, are controversial. Recently, we produced a mouse line
for conditional knockout of the gene encoding a-synuclein, and here we used its tamoxifen-inducible pan-
neuronal inactivation to study consequences of the adult-onset (from the age of 6 months) and late-onset
(from the age of 12 months) a-synuclein depletion to the nigrostriatal system. No significant changes of
animal balance/coordination, the number of dopaminergic neurons in the SNpc and the content of
dopamine and its metabolites in the striatumwere observed after adult-onset a-synuclein depletion, but in
aging (18-month-old) late-onset depleted mice we found a significant reduction of major dopamine me-
tabolites without changes to the content of dopamine itself. Our data suggest that this might be caused, at
least partially, by reduced expression of aldehyde dehydrogenase ALDH1a1 and could lead to the accu-
mulation of toxic intermediates of dopamine catabolism. By extrapolating our findings to a potential
clinical situation, we suggest that therapeutic downregulation of a-synuclein expression in PD patients is a
generally safe option as it should not cause adverse side effects on the functionality of their nigrostriatal
system. However, if started in aged patients, this type of therapy might trigger slight functional changes of
the nigrostriatal system with potentially unwanted additive effect to already existing pathology.
 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
For over two decades, since the discovery of the first missense
mutation in the gene encoding a-synuclein as the cause of a familial
form of Parkinson’s disease (PD) (Polymeropoulos et al., 1997) and
identification of a-synuclein as a major component of Lewy bodies
and Lewy neurites (Spillantini et al., 1997, 1998), malfunction of thisCardiff University, Museum
fax: þ442920874116.
kina), buchmanvl@cf.ac.uk
er Inc. This is an open access articlprotein is considered as a key molecular event in the pathogenesis of
PD and certain other diseases collectively known as a-synucleino-
pathies (Galvin et al., 2001; Goedert, 1999; Spillantini and Goedert,
2000). The prevalent hypothesis supported by multiple lines of
experimental and clinical evidence proposes the gain-of-function
mechanism associated with the formation of toxic a-synuclein spe-
cies as the cause of pathological changes in affected cells of the
nervous system (reviewed in (Caughey and Lansbury, 2003; Dev
et al., 2003; Fink, 2006; Uversky, 2007, 2017)). Nevertheless, pro-
gressive accumulation of final products of a-synuclein aggregation in
pathological inclusions might lead to a gradual depletion of a pool of
functional protein. Indeed, recent in vivo studies of neurons
expressing GFP-fused a-synuclein demonstrated reciprocale under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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synuclein in the same cell (Osterberg et al., 2015). In neurons,
including dopaminergic neurons of substantia nigra pars compacta
(SNpc), whose dysfunction is responsible for most severe symptoms
of PD, a-synuclein is normally located in presynaptic terminals
where it modulates various molecular processes involved in syn-
thesis, storage, release, and reuptake of neurotransmitters
(Abeliovich et al., 2000; Burre et al., 2010; Cabin et al., 2002; Chandra
et al., 2005; Fountaine and Wade-Martins, 2007; Greten-Harrison
et al., 2010; Lee et al., 2001; Logan et al., 2017; Nakamura et al.,
2011; Nemani et al., 2010; Perez et al., 2002; Vargas et al., 2017;
Wersinger and Sidhu, 2003; Westphal and Chandra, 2013). There-
fore, the deficiency of functional a-synuclein might compromise the
efficiency of synaptic transmission, and thus, contributes to the
nigrostriatal system disfunction in PD patients (Al-Wandi et al., 2010;
Benskey et al., 2016; Collier et al., 2016; Venda et al., 2010).
However, modeling of a-synuclein deficiency in mice by
constitutively knocking out the encoding gene did not support this
hypothesis because the complete loss of a-synuclein in these ani-
mals did not have a substantial effect on synaptic transmission in
general and dopamine neurotransmission in particular (discussed
in a recent review (Sulzer and Edwards, 2019)). Still, modest im-
pairments of the nigrostriatal system function were revealed in
aged, i.e. 2-year-old a-synuclein deficient mice (Al-Wandi et al.,
2010; Connor-Robson et al., 2016). A feasible explanation is that
during a period of high plasticity, neurons of the developing ner-
vous system get adapted to the absence of a-synuclein. Lost a-
synuclein function can be compensated by other members of the
synuclein family, b-synuclein and/or g-synuclein, but even in their
absence in triple synuclein null mutant mice, an efficient
compensation can be achieved by certain unknown mechanism(s).
This functional compensation might last for a long time with some
defects become evident only in aged triple synuclein null mutant
animals (Anwar et al., 2011; Burre et al., 2010; Connor-Robson et al.,
2016; Greten-Harrison et al., 2010).
The depletion of neurons from a-synuclein in adult or aging ani-
mals would leapfrog mechanisms of developmental compensation
that make neurons resistant to potentially negative effects of a-syn-
uclein deficiency and should better represent processes that might
take place in the nervous system of PD patients. The recent high in-
terest in the reduction of a-synuclein level as a therapeutic approach
to prevent PD progression makes it more than ever important to
obtain strong experimental evidence that a-synuclein loss-of-function
induced in neurons of the adult or aging nigrostriatal system does not
cause adverse effects in the long term. However, previous studies of
the nigrostriatal system in mammals with partial depletion of a-syn-
uclein following stereotaxic injection into the substantia nigra region
of adult animals of specific siRNA or viruses encoding specific shRNA
produced inconsistent results, and in some cases, directly opposite
results (Collier et al., 2016; Cooper et al., 2014; Gorbatyuk et al., 2010;
Lewis et al., 2008; McCormack et al., 2010; Zharikov et al., 2015).
Recently, we produced a line of mice with genetic modification
that allows efficient conditional inactivation of an a-synuclein-
encoding gene (Ninkina et al., 2015), and here, we employed this
model to study the long-term consequences to the nigrostriatal
system of complete a-synuclein depletion from neurons of adult
and aging mice.
2. Materials and methods
2.1. Production of experimental mouse cohorts and induction of
Cre-recombination
All parental mouse lines used in this study were transferred to
C57Bl6J (Charles River) genetic background by multiple (>10)generations of backcrosses. Animals were maintained in conven-
tional open-lid cages with ad libitum access to standard chow and
water. For producing animal cohorts for conditional inactivation of a-
synuclein-encoding Snca gene and relevant control animals, mice
homozygous for loxP-flanked second exon of the Snca gene with
removed neo-cassette (Snca floxDneo/floxDneo (Ninkina et al., 2015))
were crossed with mice heterozygous for constitutively inactivated
Snca gene (Abeliovich et al., 2000) and homozygous for a transgenic
cassette for expression of Cre-ERT2 recombinase under control of a
neuro-specific enolase (NSE) promoter (obtained from Jean C.
Manson, University of Edinburgh). Thus, all animals produced by this
cross expressed Cre-ERT2 recombinase in their neurons and carried
one allele of the Snca gene with loxP-flanked second exon (Snca flox),
while the second allele of the genewas either fully functional (Sncaþ;
aþ) or constitutively inactivated (Snca-; a-). At the age of 6 months,
Snca flox/-mice of the same sex from the same litter were distributed,
in equal numbers, wherever possible, into an experimental group
that received tamoxifen injections and a control group that received
vehicle injection. Each of these two groups contained three cohorts
of at least 12 males and 12 females for behavioral, histological, and
biochemical studies at the age of 10, 14, and 18 months. The third
group of Snca flox/- mice was left aging and received tamoxifen in-
jections at the age of 12months; these animalswere tested, and their
brain tissues collected at the age of 18 months along with the last
cohort ofmice injected at the age of 6months. Inactivation of Snca flox
gene by loxP recombination was achieved following activation of
Cre-ERT2 recombinase by 5 days of i.p. injection of tamoxifen
(0.5 mmol/kg dissolved in corn oil). Because for all studied param-
eters, similar results were obtained for male and female groups,
combined data for both genders are shown if not stated otherwise.
All animal work was carried out in accordance with the United
Kingdom (Scientific Procedures) Act (1986) and European Directive
EC 86/609, and has been approved by the Cardiff University Ethical
Review Committee and the Home Office (Project Licences 30/2844
and 30/3412).
2.2. Genotyping
Animal genotypes were determined by PCR analysis of DNA
from ear biopsies collected as a part of the identification process.
Genotyping for Snca gene variants was carried out as described
previously (Abeliovich et al., 2000; Ninkina et al., 2015; Roman
et al., 2017). To detect the presence of the Cre-ERT2 expression
cassette in the mouse genome and discriminate between hemizy-
gous and homozygous animals, a real-time quantitative PCR
(primers: 50-ATACCGGAGATCATGCAAGC-30 and 50- CCTGTTTC
ACTATCCAGGTTACG-3) and backcross analysis were used, as
described elsewhere (Ninkina et al., 2009).
2.3. Behavioral tests
Inverted grid and accelerated rotarod tests were carried as
described previously (Connor-Robson et al., 2016; Robertson et al.,
2004). Locomotion activity of mice in a novel environment was
assessed in an activity camera (UgoBasile) according to previously
published protocols (Anwar et al., 2011). Animals were not tested
repeatedly in behavioral tests, i.e. cohorts of animals designated for
testing at the age of 18 months were not used for testing at the age
of 10 or 14 months.
2.4. Preparation of histological sections, immunohistochemistry,
and neuronal cell counts
Mice were terminated by a Schedule 1 method, and brains were
dissected. Cerebral corticeswere carefully unfolded to expose striata;
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ceps, and after cortices were folded back, the brains were fixed and
proceeded for histology. For some animals dissected brains were cut
sagitally with a blade, and one hemisphere was used for dissecting
the midbrain region for RNA or protein extraction, whereas another
hemisphere was fixed for histology. Fixation, preparation of histo-
logical sections, staining with antibody against tyrosine hydroxylase
(TH, mouse monoclonal antibody, clone TH-2, Sigma diluted 1:1000)
and stereological counting of TH-positive neurons in the SNpc and
ventral tegmental area (VTA) were performed as described (Al-
Wandi et al., 2010; Connor-Robson et al., 2016; Robertson et al.,
2004). Briefly, the borders of the substantia nigra and ventral
tegmental area (VTA) on stained sections were outlined using dis-
tribution atlas of TH-positive cells (Hokfelt et al., 1984). The first
section for counting was randomly chosen from the first ten sections
that included the SNpc/VTA region. Starting from this section, on
every fifth section, TH-positive cells with a clearly visible nucleus
were counted through the whole region. The Axiovision imaging
program (Carl Zeiss Vision) was employed to measure diameters of
30 nuclei of dopaminergic neurons in each of these regions of every
mouse brain included in this study. The nuclei were chosen
randomly, and the distance measured as the horizontal length as
they appeared on the screen. A meanwas calculated for each animal
and used for Abercrombie’s correction (Abercrombie, 1946) to obtain
an actual number of TH positive cells in the structure.
2.5. Analysis of striatal neurochemicals by high-pressure liquid
chromatography (HPLC)
Biopsies of dorsal striatawere snap-frozen in liquid nitrogen and
kept at 80 C. Concentrations of striatal dopamine, 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)
in cleared extracts obtained by homogenization of each biopsy in
300 mL of 0.06 M HClO4 followed by centrifugation at 15000g for
5 minutes at 4 C were measured by HPLC as described previously
(Connor-Robson et al., 2016).
2.6. Analysis of mRNA expression
Total RNAwas extracted from dissected midbrains of 18-month-
old mice injected with tamoxifen at the age of 12 months and
control littermates using the RNeasy PlusMini kit (Qiagen). Analysis
of RNA expression using a custom nCounter CodeSet was carried
out in the nanoSTRING nCounter Core Facility of the University
College London. The first-strand cDNA for real-time quantitative
RT-PCR analysis was synthesized using random primers (Promega)
and SuperScriptIII reverse transcriptase (Invitrogen). For PCRFig. 1. Depletion of a-synuclein in the striatum following conditional inactivation of the enco
dorsal striata of 10-month-old Sncaflox/- mice carrying a copy of NSE/Cre-ERT2 transgenic cas
striata were analyzed. For loading control, the same blot was re-probed with an antibody aamplification reaction Go Taq Hot Start polymerase (Promega),
DyNAmo HS SYBR Green supermix, and ROX (Finnzymes) as a
passive reference dye, were used. Each sample was analyzed in
quadruplicate on an ABI StepOnePlus real-time PCR instrument,
and data were analyzed using integrated StepOne Software v2.3
(Applied Biosystems). cDNA amount for each gene was normalized
to that of GAPDH. Primer sequences used were as follows:
ALDH1a1: 50- GGCCTTCACTGGATCAACAC-30 and 50-
GGGTGACTCTCTTCAGATTG-3’; GAPDH: 50- TCGCCAGCCGAGCCA-30
and 50- GAGTTAAAAGCAGCCCTGGTG -3’.
2.7. Western blotting
Total protein samples were prepared by homogenization of
mouse striata in the SDS-PAGE loading buffer following incubation
for 10 minutes at 100 C. Gel electrophoresis, transfer to PVDF
membrane, incubation with primary and secondary HRP- or Cy5-
conjugated antibodies (GE Healthcare and Molecular Probes,
correspondingly), and detection of protein bands was performed as
described previously (Ninkina et al., 2003, 2012). Primary anti-
bodies against a-synuclein (mouse monoclonal antibody, clone 42,
BD Transduction Laboratories, diluted 1:1000), b-synuclein (rabbit
monoclonal, clone EP1537Y, Abcam, diluted 1:5000), TH (mouse
monoclonal, clone TH-2, Sigma, diluted 1:5000), synaptophysin
(mouse monoclonal, clone 2, BD Transduction Laboratories, diluted
1:10,000), aldehyde dehydrogenase ALDH1a1 (rabbit polyclonal
ABD12, Merck, diluted 1:4000) and b-actin (mouse monoclonal,
clone AC-15, Sigma, diluted 1:10,000) were used.
2.8. Statistical analysis
All data are presented as means  SEM. ANOVA, paired t-test, or
nonparametric Mann-Whitney test was used for assessing the
statistical significance of the difference between groups, as appro-
priate. The nSolver 4.0 software (NanoString Technologies) was
used for analyzing mRNA expression data obtained by NanoString/
nCounter technique. Statistical analysis was performed using
GraphPad Prism 7.0e.
3. Results
3.1. Depletion of a-synuclein in the dorsal striatum following
activation of Cre-ERT2 recombinase in neurons of adult Snca flox/-
mice
At the age of 6 months, heterozygous Sncaflox/- mice carrying a
copy of NSE/Cre-ERT2 transgenic cassette received tamoxifen ording gene. Western blot analysis of a-synuclein in the total protein samples of dissected
sette following tamoxifen or vehicle injection at the age of 6 months. Individual mouse
gainst b-actin.
Fig. 2. Striatal dopamine metabolism and populations of midbrain dopaminergic neurons are not affected by conditional inactivation of Snca gene in neurons of 6-month-old mice.
(A) Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) content and the ratio of metabolites (DOPACþHVA) to dopamine in the dorsal striatum of
10-, 14- and 18-month-old Sncaflox/- mice carrying a copy of NSE/Cre-ERT2 transgenic cassette injected with tamoxifen (TMX) or vehicle (veh) at the age of 6 months. Bar charts show
meanSEM of neurochemical concentrations measured by HPLC with electrochemical detection or of their ratio. The number of samples analyzed for each group is shown at the
bottom of the corresponding bar. Statistical analysis using one-way ANOVA revealed no statistically significant difference between groups for dopamine (F (5, 149) ¼ 1.669; p ¼
0.1455), DOPAC (F (5, 149) ¼ 2.125; p ¼ 0.0655), HVA (F (5, 127) ¼ 0.5943; p ¼ 0.7043) but statistically significant increase in metabolites to dopamine ratio (F (5, 127) ¼ 2.723; p ¼
0.0226) was observed. The post-hoc Sidak’s multiple comparisons test showed significant increase of this ratio in tamoxifen-injected compared to vehicle-injected mice at the age of
18 months (*p ¼ 0.0473). (B) The number of TH-positive neurons in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) of 14- and 18-month-old Sncaflox/-
mice injected with tamoxifen (TMX) or vehicle (veh) at the age of 6 months. Results for a control group of Sncaflox/þ mice (aþ) injected with tamoxifen at the age of 6 months and
analyzed at the age of 18 months are also included. Bar charts show meanSEM of stereologically counted neuron numbers in each structure. The number of samples analyzed for
each group is shown at the bottom of the corresponding bar. Statistical analysis using one-way ANOVA revealed no statistically significant difference between groups (F (4, 231) ¼
1.857; p ¼ 0.1189 for SNpc and F (4, 231) ¼ 0.8610; p ¼ 0.4881 for VTA).
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later (i.e., at the age of 10 months), several male and female animals
were sacrificed, dorsal striata were dissected, and expression of a-
synuclein in total protein extracts was analyzed byWestern blotting
with an antibody specific to mouse a-synuclein. As illustrated in
Fig. 1, in contrast to a high level in the vehicle-injected mice, a-
synuclein becomes undetectable in the dorsal striatum of the ma-
jority of tamoxifen-injected mice with only trace amount remains
in this brain structure of some animals, which might be caused by
the presence of erythrocyte-derived a-synuclein originated from
blood in the latter samples. A similar pattern was observed whenthe expression of a-synuclein was assessed in the striatum of 18-
month-old mice that received tamoxifen at the age of 6 months
(see below).
3.2. Inactivation of an a-synuclein gene at the age of 6 months does
not affect striatal content of dopamine and its metabolites
The contents of dopamine, DOPAC and HVA in the dorsal stria-
tum of 10-, 14- and 18-month-old mice that received tamoxifen or
vehicle at the age of 6 months were analyzed by HPLC with elec-
trochemical detection. Statistically, no significant changes were
Fig. 3. Expression of presynaptic proteins in the dorsal striatum of 18-month-old Sncaflox/- and Sncaflox/þmice injected with tamoxifen and Sncaflox/- mice injected with vehicle at the
age of 6 months. (A) The upper panel shows a representative Western blot image illustrating the expression of tyrosine hydroxylase (TH) and synaptophysin with b-actin as a
loading control. Individual mouse striata were analyzed. The Cy5-conjugated secondary antibody was used for the detection of these proteins. A bottom part of the same membrane
was probed with an antibody against mouse a-synuclein (middle panel), and then, without stripping, was re-probed with an antibody against b-synuclein (bottom panel). HRP-
conjugated secondary antibody and chemiluminescent detectionwere used for the detection of both synucleins. For quantification, protein bands were scanned, levels of TH (B) and
synaptophysin (C) were normalized to levels of b-actin in studied striatal samples and then to the average level in control Sncaflox/þ mice. Bar charts show meansSEM of
normalized values obtained by Western blot analysis of 6 vehicle-injected (veh) and 6 tamoxifen-injected (TMX) Sncaflox/- mice and 4 tamoxifen-injected Sncaflox/þ (TMX (aþ)) mice.
Statistical analysis using the Kruskal-Wallis test revealed no statistically significant difference between groups (p ¼ 0.9704; Kruskal-Wallis statistic 0.06548 for TH and p ¼ 0.2438;
Kruskal-Wallis statistic 2.890 for synaptophysin).
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for each of these neurochemicals at any of the studied age points
(Fig. 2A). Although a trend for increased metabolites to dopamine
ratio in tamoxifen-injected mice was noted at each age point, the
difference reaches significance only for the largest studied groups
of 18-month-old animals (p ¼ 0.0473, one-way ANOVA with post-
hoc Sidak’s multiple comparisons test; Fig. 2A).Fig. 4. Assessment of balance and coordination of mice following conditional inactivation of
performance of 10-, 14- and 18-month-old Sncaflox/- mice injected with tamoxifen (TMX) o
Sncaflox/þ mice (TMX (aþ)) are also shown. The number of assessed animals in each group
ANOVA revealed no statistically significant difference between groups (F (6, 167) ¼ 0.6728;3.3. No changes in the number of TH-positive neurons in the SNpc
and VTA, TH expression in the striatum and performance in the
balance and coordination tests of mice following inactivation of an
a-synuclein gene at the age of 6 months
The number of dopaminergic neurons in two midbrain ganglia,
SNpc and VTA, was assessed in Sncaflox/- and Sncaflox/þmice carryingSnca gene in their neurons at the age of 6 months. Accelerated rotarod and inverted grid
r vehicle (veh) at the age of 6 months. Results for 18-month-old tamoxifen-injected
is shown at the bottom of the corresponding bar. Statistical analysis using one-way
p ¼ 0.6718 for rotarod test and F (6, 166) ¼ 1.138; p ¼ 0.3426 for inverted grid test).
Fig. 5. Expression of presynaptic proteins in the dorsal striatum of 18-month-old Sncaflox/- mice injected with tamoxifen or vehicle at the age of 12 months. (A) The upper panel
shows a representative Western blot image illustrating the expression of tyrosine hydroxylase (TH) and synaptophysin with b-actin as a loading control. Individual mouse striata
were analyzed. The Cy5-conjugated secondary antibody was used for the detection of these proteins. A bottom part of the same membrane was probed with an antibody against
mouse a-synuclein and HRP- conjugated secondary antibody following chemiluminescent detection. For quantification, protein bands were scanned, levels of TH (B) and syn-
aptophysin (C) in each striatal sample were normalized to the level of b-actin in this sample and then to the average level in control vehicle-injected mice. Bar charts show
meansSEM of normalized values obtained by Western blot analysis of 6 vehicle-injected (veh) and 8 tamoxifen-injected (TMX) Sncaflox/- mice. Statistical analysis using the Mann-
Whitney test revealed no statistically significant difference between groups (p ¼ 0.5080; sum of ranks (137, 163); Mann-Whitney U ¼ 58 for TH and p ¼ 0.2284; sum of ranks (55,
50); Mann-Whitney U ¼ 14 for synaptophysin).
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months after tamoxifen or vesicle injections, i.e. at the age of 14 and
18 months. Stereological counting of TH-positive neurons on
immunostained histological sections revealed no difference be-
tween studied groups in both ganglia (Fig. 2B, Suppl. Fig. A1).
Consistently with the lack of changes in the number of TH-
positive neurons in the SNpc and dopamine content in the dorsal
striatum, no difference in TH expression in the dorsal striatum of
18-month-old mice was detected byWestern blot analysis between
mice injected with tamoxifen and vehicle (Fig. 3). The expression of
synaptophysin and b-synuclein in this brain structure was also
found unaffected by a-synuclein depletion.
Not surprisingly, in the absence of biochemical and morphological
changes in the nigrostriatal system, inactivation of an a-synuclein-
encoding gene at the age of 6 months did not affect animal
performance in the accelerated rotarod and inverted grid tests (Fig. 4).3.4. Inactivation of a-synuclein gene at the age of 12 months does
not affect the number of TH-positive neurons in the SNpc, dopamine
content in the dorsal striatum of 18-month-old mice and their
balance and coordination
For testing whether triggering of alpha-synuclein depletion in
neurons of older animals would cause changes in their nigrostriatal
system, a group of animals from the same cohort of Sncaflox/- mice
was injected with tamoxifen at the age of 12 months and assessed
at the age of 18 months.
Similar to the inactivation of the gene at the age of 6 months,
this protocol led to efficient depletion of striatal a-synuclein and
caused no changes to striatal TH and synaptophysin levels (Fig. 5).
Consistently, no changes in TH-positive neuron number in the SNpc
(Fig. 6A, Suppl. Fig. A1) and striatal dopamine context (Fig. 6B) were
found in 18-month-old Sncaflox/- mice after inactivation of an a-
synuclein-encoding gene at the age of 12 months when compared
with vehicle-injected Sncaflox/- mice or Sncaflox/- mice injected with
tamoxifen at the age of 6 months.1 The performance in the1 It should be noted that it was not possible to assess accurately the number of
neurons in the VTA of this smaller group of animals because following dissection
their brains were cut sagittally and only one half of the brain was fixed for
immunohistochemical analysis; this affected the integrity of VTA located close to
the cut line, in contrast to more laterally located SNpc.accelerated rotarod test was not significantly affected (Fig. 6C), and
all animals in the group injected with tamoxifen at 12 months
successfully completed the inverted grid test, suggesting that their
balance and coordination are not compromised.3.5. Changes in dopamine catabolism in the dorsal striatum of 18-
month-old mice following inactivation of an a-synuclein gene at the
age of 12 months
In spite of a normal content of dopamine, its catabolism in
the dorsal striatum of 18-month-old mice becomes affected as
the result of a-synuclein depletion from the age of 12 months, as
evident from significantly reduced content of both major dopa-
mine metabolites, DOPAC and HVA (Fig. 6D and E). This causes a
substantial decrease in the metabolite to dopamine ratio
(Fig. 6F).
A crucial final step in DOPAC and HVA production is an oxidation
reaction that in dopaminergic neurons is primarily catalyzed by
cytosolic aldehyde dehydrogenase ALDH1a1. The deficiency of this
enzyme leads to the accumulation of dopamine catabolism in-
termediates, reactive aldehydes, DOPAL and HVAldehyde that are
toxic to neurons. A significant downregulation of ALDH1a1 mRNA
expression in the midbrain region of 18-month-old animals injec-
ted with tamoxifen at the age of 12 months when compared to
control littermates injected with a vehicle was detected by quan-
titative RT-PCR (Fig. 7A). This downregulation in a regionwhere cell
bodies of SNpc dopaminergic neurons are located is consistent with
a trend for reduction of the protein level in the dorsal striatum,
although the difference revealed by quantitation of Western blot
data from available samples did not reach statistical significance
mainly because of inconsistent low ALDH1a1 level in one of the
control samples (Fig. 7E and F). In contrast, no changes in the
expression of mRNA encoding enzymes involved in the production
of reactive aldehydes from dopamine, catechol-O-methyl trans-
ferase (COMT) and monoamine oxidases (MAO) were found
(Fig. 7BeD). The latter results were obtained by NanoString/
nCounter analysis of a bespoke codeset of mRNAs encoding proteins
involved in neurotransmission. In this analysis, neither of 106
studied mRNAs displayed statistically significant fold change of
expression in tamoxifen-injected versus control, vehicle-injected
group (for a full list of studied mRNA with mean fold changes and
statistics see Supplementary Table A1).
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In the previous study, we demonstrated that constituent inac-
tivation of genes coding for all three members of the synuclein
family caused hyperactivity of young adult triple knockout mice
(Anwar et al., 2011). Conditional inactivation of only an a-synuclein-
encoding gene in adult animals triggered the gradual development
of a similar phenotype. 10-month-old Sncaflox/- mice injected with
tamoxifen at the age of 6 months showed the same locomotor ac-
tivity in a nonanxiogenic activity camera as vehicle-injected mice
(Fig. 8A), but 14-month-old mice displayed a hyperactive pheno-
type (Fig. 8B) that became profound in 18-month-old mice (Fig. 8C).
Mice injected with tamoxifen at the age of 12 months developed a
similar hyperactive phenotype at the age of 18 months (Fig. 8D).
4. Discussion
4.1. Depletion of a-synuclein in adult neurons
Tamoxifen-induced activation of pan-neuronally expressed Cre-
ERT2 recombinase in adult (6-month-old), or aging (12-month-old)
mice allowed us to effectively inactivate a floxed Snca gene in theirFig. 6. No changes in SNpc dopaminergic neuron complement, striatal dopamine content an
striatum of 18-month-old mice following conditional inactivation of Snca gene in their neuro
neurons in the SNpc (A), striatal dopamine (B), DOPAC (D), HVA (E) contents, DOPACþHVA
month-old Sncaflox/- mice injected with vehicle (veh) and tamoxifen (TMX) at the age of eith
at the bottom of the corresponding bar. Statistical analysis using one-way ANOVA revealed no
performance (F (2, 74) ¼ 0.9736; p ¼ 0.3825) and dopamine content (F (2, 70) ¼ 0.6066; p ¼
**p ¼ 0.0001), HVA content (F (2, 61) ¼ 12.02; **p <0.0001) and metabolites to dopamine
12 months showed decrease in DOPAC content (p ¼ 0.0064), HVA content (p ¼ 0.0011) and the
(p <0.0001), HVA content (p <0.0001) and the ratio (p <0.0001) compared to animals injectneurons, which caused the reduction of a normally high level of a-
synuclein in the dorsal striatum to a virtually undetectable level in
the majority of treated animals. Assuming that changes in the
nigrostriatal system of mice with complete germline inactivation of
Snca gene (i.e., constituent a-synuclein knockout mice) are minimal
because of an efficient compensation of a-synuclein function during
a period of high plasticity of the developing nervous system, we
expected to observe more profound changes in animals depleted of
a-synuclein long after the end of this period. However, similar to
previous observations made in constituent a-synuclein knockout
mice, striatal contents of dopamine, its metabolites, TH, synapto-
physin, as well as balance and coordination of mice, appeared un-
changed at any of studied age points following inactivation of Snca
gene at the age of 6 months. Moreover, neither striatal dopamine
content nor balance and coordinationwere affected in 18-month-old
mice following inactivation of Snca gene at the age of 12 months.
4.2. a-synuclein is not required for survival of mature dopaminergic
neurons in the mouse SNpc
Previous studies demonstrated reduced complement of SNpc
TH-positive neurons in two lines of mice constituently lacking a-d rotarod performance but significant decrease of striatal dopamine metabolites in the
ns at the age of 12 months. Bar charts show meanSEM of the number of TH-positive
to dopamine ratio (F) and the latency to fall from an accelerated rotatod (C) for 18-
er 6 or 12 months. The number of samples/animals analyzed for each group is shown
difference between groups in neuron number (F (2, 128) ¼ 2.011; p ¼ 0.1380), rotarod
0.5480) but significant difference between groups in DOPAC content (F (2, 70) ¼ 10.50;
ratio (F (2, 61) ¼ 11.99; **p <0.0001). Animals injected with tamoxifen at the age of
ratio (p ¼ 0.0096) compared to animals injected with vehicle only and in DOPAC content
ed with tamoxifen at the age of 6 months (all by Sidak’s multiple comparisons test).
Fig. 7. Decreased expression of aldehyde dehydrogenase ALDH1a1 in 18-month-old mice following conditional inactivation of Snca gene in their neurons at the age of 12 months.
(A) Fold changes (mean  SEM) of the expression of aldehyde dehydrogenase 1a1 (ALDH1a1) mRNA in the midbrain of tamoxifen-injected (TMX (12 m)) versus vehicle-injected
(veh) mice assessed by real-time qRT-PCR. RNAs extracted from midbrains of 6 animals per group were analyzed in two technical repeats (*p ¼ 0.0167; sum of ranks (191, 109);
Mann-Whitney U ¼ 31). (B-D) Direct measurement of mRNA content by nanoString/nCounter technique revealed no significant expression differences (p >0.05, Mann-Whitney
test) for mRNAs encoding catechol-O-methyl transferase (COMT), monoamine oxidase A (MaoA) and monoamine oxidase B (MaoB). (E, F) Images of two representative Western
blots illustrating the expression of ALDH1a1 in the dorsal striatum with b-actin as a loading control. For quantification, protein bands were scanned, levels of ALDH1a1 were
normalized to levels of b-actin in studied striatal samples and then to the average level in control vehicle-injected mice. Bar chart show meansSEM of normalized values obtained
by Western blot analysis of 6 vehicle-injected and 10 tamoxifen-injected Sncaflox/- mice (p ¼ 0.1471; sum of ranks (65, 71); Mann-Whitney U ¼ 16).
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Garcia-Reitboeck et al., 2013; Robertson et al., 2004) and recently
we made the same observation (manuscript in preparation) in a
newmouse line with a constituent a-synuclein knockout produced
by germline inactivation of Snca gene in Sncaflox mice (line SncaDflox/
Dflox; C57BL/6-Snca<tm1.1Vlb>/J; JAX Stock#025636) described in
our previous publication (Ninkina et al., 2015). It has been shown
that this deficit of neurons is established in the embryonic brain
and is not progressive, suggesting the importance of a-synuclein for
efficient genesis or survival of dopaminergic neurons or a certain
specific population of these neurons only during a particular period
of development (Garcia-Reitboeck et al., 2013). This implies that the
depletion of a-synuclein in adult animal neurons should not cause
their loss. Indeed, inactivation of Snca gene at the age of either 6 or
12 months did not lead to a reduction in the number of TH-positive
neurons in the SNpc of 18-month-old mice. Therefore, similar to the
majority of developing neurons, adult dopaminergic neurons of the
SNpc are able to efficiently compensate for the absence of a-
synuclein.
4.3. Late-onset depletion of a-synuclein affects dopamine
catabolism in the dorsal striatum
Although an adult-onset depletion of a-synuclein does not affect
the complement of dopaminergic neurons in the SNpc, it might stillaffect certain molecular processes in the neuronal compartment
where this protein is normally most abundant and plays important
roles in neurotransmission, namely in presynaptic terminals
located in the dorsal striatum. Whereas a-synuclein depletion from
the age of 6 months did not change the content of major dopamine
metabolites in the dorsal striatum of aging mice, its depletion from
the age of 12 months caused substantial decrease of both DOPAC
and HVA. With the level of dopamine not affected, this caused a
sharp decrease of the metabolites to dopamine ratio in these 18-
month-old mice, in contrast to a slight increase of this ratio in 18-
month-old mice with a-synuclein depletion from the age of
6 months. These observations suggest that in adult mice, dopami-
nergic neurons of SNpc are able to normalize dopamine turnover in
their presynaptic terminals affected by the loss of a-synuclein, but
in the aging nervous system this ability is compromised. It is
feasible that in the dopaminergic presynaptic terminals in the
dorsal striatum of mice depleted from a-synuclein later in their life
dopamine catabolism is slowed down leading to accumulation of
DOPAL and HVAldehyde, highly neurotoxic reactive aldehydes
(Burke et al., 2003; Marchitti et al., 2007). Aldehyde de-
hydrogenases, particularly cytoplasmic ALDH1a1, are responsible
for detoxication of DOPAL and HVAldehyde by their conversion to
DOPAC and HVA, correspondingly. The role of these enzymes in the
normal function of dopaminergic neurons (Anderson et al., 2011;
Liu et al., 2014; McCaffery and Drager, 1994) and implication of
Fig. 8. Analysis of animal locomotion in the activity camera. Groups of Sncaflox/- mice injected with tamoxifen or vehicle at the age of 6 months were tested at the age of 10 (A), 14 (B)
and 18 (C) months and a group of Sncaflox/- mice injected with tamoxifen at the age of 12 months was tested at the age of 18 months (D). The number of animals in each group is
shown in brackets. Graphs show mean  SEM of the number of infrared beam crosses per 4-min interval. Two-way ANOVA revealed no significant difference in locomotion (beam
breaks) between tamoxifen-injected and vehicle-injected groups tested at 10 months of age (F (1, 43) ¼ 0.2120, p ¼ 0.6475), but this difference was significant for 14 months (F (1,
38) ¼ 4.231, p ¼ 0.0466), 18 months (F (1, 55) ¼ 8.212, p ¼ 0.0059) and 18 months injected at 12 months (F (1, 41) ¼ 12.18, p ¼ 0.0012) groups. The presence of statistically significant
difference for particular time interval identified by post-hoc Fisher test is also indicated (*p <0.05, **p <0.01).
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been documented (Burke et al., 2008; Fitzmaurice et al., 2013;
Galter et al., 2003; Wey et al., 2012). Although the experimental
setup of our study did not allow for measuring levels of DOPAL and
HVAldehyde, we have demonstrated that expression of mRNAs
encoding enzymes involved in the production of aldehydes from
dopamine was not affected in mice depleted of a-synuclein from
the age of 12 months, but the expression of ALDH1a1 mRNA was
reduced, and the level of this enzyme in the striatum followed the
same trend. We appreciate that experimental evidence obtained so
far is not conclusive enough to claim that the deficiency of ALDH1a1
is the reason for the reduced content of DAmetabolites and that this
reduction is linked with the accumulation of toxic aldehydes in the
striatum of mice with late-onset depletion of alpha-synuclein.
However, this is a possible scenario that deserves to be taken into
consideration. Further studies will demonstrate if alterations of
dopamine turnover indeed cause accumulation of toxic metabolites
with potential effects on structure or/and function of dopaminergic
synapses, but in the absence of obvious phenotype, one can suggest
that any such changes would not be dramatic. However, it could not
be excluded that in the aging brain affected by PD pathology,
depletion of a functional pool of monomeric a-synuclein in pre-
synaptic terminals could exacerbate malfunction of dopamineneurotransmission caused by the toxicity of oligomeric products of
alpha-synuclein aggregation. Interestingly, it has been shown that
DOPAL can induce aggregation of a-synuclein (Burke et al., 2008),
and therefore, it is possible that a previously unrecognized vicious
circle might develop in dopaminergic neurons after a-synuclein
aggregation first triggered by seeding or an alternative mechanism.
4.4. No significant changes of neurotransmission-related mRNA
expression in the midbrain of aging mice after a late-onset depletion
of a-synuclein
Although no statistically significant differences in expression of
neurotransmission-related mRNAs between a-synuclein-depleted
and control midbrains have been detected by NanoString/nCounter
approach, this comparative analysis revealed some trends that
justify future detailed studies of particular mRNA and protein
expression in more defined neuronal populations. Of particular
interest is a slight increase in expression of mRNAs for two major
dopamine receptors, D1 and D2 (Drd1 and Drd2), in tamoxifen
injected animals, whereas mRNAs for dopamine (DAT, Slc6a3) and
vesicular monoamine (VMAT2, Slc18a2) transporters were found
predominantly downregulated in these animals. Such small but
coordinated changes might reflect either consequence of the loss of
N. Ninkina et al. / Neurobiology of Aging 91 (2020) 76e87 85a-synuclein function in presynaptic terminals of dopaminergic
neurons of aging mice or functional compensation for this loss in
the nigrostriatal system of these animals. It should be noted that
expression was studied only in 18-month old mice, i.e. when nat-
ural aging might interfere with the efficacy of compensatory pro-
cesses, and for mRNA encoding proteins involved in such processes,
changes of expression could be more profound at earlier stages of
adaptation to a-synuclein loss.
An example of age-related fading of compensation for the
absence of a-synuclein can be illustrated by changes of mouse
behavior observed in mice after adult-onset depletion of this pro-
tein. In a previous study, we revealed that the loss of all three
synucleins leads to a significant increase of locomotor activity of
young triple constituent knockout mice in a novel nonaxiogenic
environment (Anwar et al., 2011). Here we demonstrated that mice
depleted of a-synuclein from adulthood gradually develop similar
hyperactive phenotype, indicating that certain mechanism, which
may be linked to the presence of b-synuclein and g-synuclein,
initially compensate for the a-synuclein loss but their efficiency
decline in the aging animals.4.5. Is the reduction of a-synuclein level in adult neurons a safe
long-term therapeutic approach?
Cutting the level of endogenous a-synuclein in PD patients has
been suggested as a potential therapeutic approach to prevent the
progression of the disease (Bae et al., 2012; Masliah et al., 2005,
2011; Tran et al., 2014). Both RNA interference (Takahashi et al.,
2015) and immunotherapeutic (reviewed in (Sardi et al., 2018;
Wang et al., 2019)) approaches have been suggested, and clinical
trials for some of them are already ongoing.
However, the results of some published studies raised uncer-
tainty about the potential adverse effects of a-synuclein down-
regulation on the nigrostriatal system function. In two papers from
the same laboratory authors attempted to halt a-synuclein
expression in SNpc neurons of adult rats and green monkeys using
an RNAi-mediated degradation of a-synuclein-encoding mRNA
following unilateral injection of shRNA-expressing AAV5 virus
particles in the SNpc (Collier et al., 2016; Gorbatyuk et al., 2010).
Surprisingly, in these experiments striking neuronal loss of dopa-
minergic neurons in the SNpc, dramatic reduction of TH and
dopamine content in the striatum and the case of rats, profound
amphetamine-induced rotational asymmetry were observed in
spite of only partial reduction of a-synuclein expression in SNpc
neurons and scant decrease of its level in the striatum (Gorbatyuk
et al., 2010). In another study, injection of shRNA-expressing
AAV2 virus particles into the rat SNpc decreased the level of a-
synuclein in the cell bodies of dopaminergic neurons by ~35%, but
this did not cause any loss of SNpc neurons, or reduction of TH
expression level, or movement deficit (Zharikov et al., 2015). Advert
effects on the nigrostriatal system have not been observed in other
studies that used in vivo delivery of naked (Lewis et al., 2008;
McCormack et al., 2010) or exosome-packed siRNA against a-syn-
uclein (Cooper et al., 2014). Possible explanations of these dis-
crepancies have already been discussed (Zharikov et al., 2015).
Importantly, in contrast to all studies based on RNA interference,
in our study, we achieved a complete cease of a-synuclein pro-
duction in neurons and its depletion from the dorsal striatum. The
permanent nature of this cease following loxP/Cre-driven inacti-
vation of the gene allowed us to assess the long-term consequences
of a-synuclein loss. We demonstrated that the nigrostriatal system
is able to function properly for a long period of time after complete
adult-onset depletion of a-synuclein from SNpc dopaminergic
neurons and their presynaptic terminals.5. Conclusions
Results of our study in amousemodel suggest that the reduction
of the a-synuclein level does not per se causes long-term adverse
effects on the functionality of adult neurons of SNpc, and therefore,
can be considered as a safe option for therapeutic intervention.
However, slight functional changes of the nigrostriatal system could
be expected in the case of a late-onset depletion of a-synuclein, and
it is not known if they might exacerbate pre-existing pathology in
mid/late-stage PD patients. Therefore, to decrease the possibility of
unwanted adverse effects, treatments aimed at reduction of a-
synuclein level should be started at the early stages of PD.
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